New BACE1 Inhibitors for the Treatment of Alzheimer's Disease

Back to all technologies
Download as PDF
2017-GHOS-67821
According to the Alzheimer's Association, nearly one in every nine Americans above the age of 65 have Alzheimer's disease. The causes of this disease are poorly understood and there is currently no cure for it. Current treatments may temporarily improve symptoms, but cannot stop or reverse the progression of this disease and their side effects include nausea, headaches, confusion and vomiting. There is a clear need for improvement in the treatment of Alzheimer's disease.

Researchers at Purdue University have synthesized new compounds capable of improving current treatments of Alzheimer's. These compounds are of a stable BACE1 inhibitor, which has been shown to help treat the disease in mice. Compared to other BACE1 inhibitor treatments, this compound is selective, expected metabolically stable, and very potent. This would likely lead to the reduction of side effects from treatment, such as headaches and dizziness, because of the inhibitor's selectiveness. These compounds have vastly improved drug properties compared to other BACE1 inhibitors currently available.

Advantages:
-Very potent
-Metabolically stable
-Selective BACE1 inhibitor

Potential Applications:
-Treatment of Alzheimer's disease
Apr 13, 2020
NATL-Patent
United States
(None)
(None)

Oct 12, 2018
PCT-Patent
WO
(None)
(None)

Oct 13, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org